The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Eli Lilly, Novo Nordisk Shares Slide as Trump Picks RFK Jr. for HHS Post
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $39
